… the drug was regulated after use raised significant medical concerns. … of psychedelics as new treatments. However, as David Olson … starting points to make better medicines,” says Olson. “We … chief innovation officer of Delix Therapeutics, a company that …

… and outperformed ketamine in antidepressant potency — all while … psychedelic drug LSD. Drugs like JRT might enable new treatments for … chief innovation officer of Delix Therapeutics, a company … Najafi Research Award in Medicinal Chemistry, the Boone Family …

… antidepressant effects, and improved cognitive flexibility—key challenges in schizophrenia treatment … Neuroscience NewsTo design the drug, dubbed JRT, researchers … and biochemistry and molecular medicine at UC Davis. … innovation officer of Delix Therapeutics, a …

… hallucinogenic drug could help bridge the treatment gap. So companies like Delix Therapeutics … are making new drugs … optimistic that non-hallucinogenic drugs may widen treatment options for patients. …

… chief medical officer of Delix Therapeutics. "The challenge is that these drugs … effects." Koenig believes current antidepressants, while they can improve lives … solve the current issues with antidepressants via the novel neuroplastogen, DLX …

… in a doctor’s office. An oral treatment option gives … in 2025, the pharmaceutical and biotech industries have a significant … precision medicine. Just as CRISPR and GLP-1 drugs revolutionized … 2 trials.” Mark Rus, CEO, Delix Therapeutics Clinical trial changes …

… measurable concentrations of drug in the cerebrospinal fluid … Delix’s neuroplastogens, can be developed into novel treatments … vitro, rapid and enduring antidepressant responses in preclinical models … bring patients FDA-approved, take-home medicines that are …

… has rapid and enduring antidepressant-like effects in … our phenotypic drug discovery engine, Delix is committed to … and differentiated treatments.4 About Delix Therapeutics Delix Therapeutics is … bring patients FDA-approved, take-home medicines that will …

… biotech company, has taken a significant step in advancing treatments … drug, PSIL-006. Unlike traditional psychedelics, this pharmaceutical … trials and, potentially, FDA approval. If successful, the drug … , chief medical officer at Delix Therapeutics, explained …

… trial to further study the safety and efficacy of the treatment. “The FDA … in two phase 3 clinical trials. In the studies, patients … FDA, by not approving the treatment, would be signaling to drug … for future drugs. Mark Rus, CEO of Delix Therapeutics Mark …